TIMI Score in Acute ST Elevation Myocardial Infarction and Its Correlation with Single Quantitative Troponin T and Ejection Fraction < 40% by Dilip Kumar, R
“ TIMI SCORE IN ACUTE ST ELEVATION MYOCARDIAL 
INFARCTION AND ITS CORRELATION WITH SINGLE 
QUANTITATIVE TROPONIN T AND EJECTION FRACTION < 40%” 
 
A Dissertation Submitted to 
THE TAMILNADU DR. M.G.R MEDICAL UNIVERSITY 
CHENNAI 
 
In Partial Fulfillment of the Regulations 
for the Award of the Degree of 
M.D. (GENERAL MEDICINE) - BRANCH – I 
 
 
GOVERNMENT KILPAUK MEDICAL COLLEGE 
CHENNAI-10 
April – 2016 
BONAFIDE CERTIFICATE 
           This is to certify that “TIMI SCORE IN ACUTE ST ELEVATION 
MYOCARDIAL INFARCTION AND ITS CORRELATION WITH SINGLE 
QUANTITATIVE TROPONIN T AND EJECTION FRACTION < 40% ” is a 
bonafide work performed by Dr. DILIP KUMAR R, post graduate student, 
Department of  Internal Medicine, Kilpauk Medical College, Chennai-10, under 
my guidance and supervision in fulfillment of regulations of the Tamil Nadu Dr. 
M.G.R Medical university for the award of M.D. Degree Branch I (General 
Medicine) during the academic period from July 2013 to April 2016. 
 
 
 
 
Prof.Dr.S.Ushalakshmi M.D.,FMMC.,            Prof.Dr.T.Ravindran M.D,D.N.B  
Professor and HOD,                                      Professor and Unit chief 
Department of Medicine ,                                     Department of Medicine, 
KMC & GRH                              Kilpauk Medical College,                                     
Chennai 10.                                        Chennai 10.                                                       
 
 
 
 
Prof. Dr.R.Narayana Babu M.D.,DCH, 
The DEAN, 
Govt.Kilpauk Medical College and Hospital, 
Chennai - 600 010. 
DECLARATION 
 
I, Dr. DILIP KUMAR R, declare that, I carried out this work on, “ TIMI 
SCORE IN ACUTE ST ELEVATION MYOCARDIAL INFARCTION AND 
ITS CORRELATION WITH SINGLE QUANTITATIVE TROPONIN T 
AND EJECTION FRACTION < 40% ” at the Department of Medicine, Kilpauk 
medical college & hospital during the period of January 2015 to August 2015. This 
is submitted to The Tamilnadu Dr.M.G.R.Medical University, Chennai in partial 
fulfillment of the requirement for the award of M.D degree (Branch –I) General 
Medicine. 
 
 
 
Place : Chennai                                                            Dr. DILIP KUMAR R 
Date: 
 
 
 
                                    
 
ACKNOWLEDGEMENT 
 
          I wish to express my sincere thanks to Prof. Dr. R Narayana Babu M.D., 
DCH., Dean- Govt. Kilpauk  Medical college and Hospital, for providing me with 
all the necessary facilities for the research. 
            I am also grateful to Prof. Dr. S. Ushalakshmi MD., FMMC, Professor 
and Head of the Department of Medicine for permitting me to do the following 
study. I am extremely thankful and indebted to her for sharing expertise, and 
sincere and valuable guidance and encouragement extended to me. 
          I have to thank my academic guru - Professor of Internal Medicine and 
cardiology Prof. Dr. T. Ravindran M.D., DNB., Dip.Diab whose patience, 
understanding and clinical acumen has helped me immensely in finishing this 
work. He has been a constant support to me from the start till the end.  
       I also thank Prof. Dr .C. Hariharan M.D., Professor of Medicine , for his 
guidance and support.  I also thank Prof. Dr. Kulothungan M.D and (late) Prof . 
Dr . Surendran M.D for their valuable advices , guidance and support.  
       I am extremely thankful to Assistant Professors of Medicine, Dr. G. Panneer 
Selvam  M.D., Dr. P.I. Rajan Babu M.D., and Dr. Narendran M.D., for their 
assistance and guidance.  
           I also take this opportunity to express gratitude to all of the Department 
faculty members for their help and support. I also thank my colleagues for the 
unceasing encouragement, support and attention. I would especially like to thank 
my colleagues Dr. Umalakshmi Premnath, Dr.Ibrahim Sammem Kan, Dr. 
Saranya Masilamani , Dr. Balamurugan , Dr. Karthikeyan, Dr. Sivaraman , Dr. 
Jeevitha ,Dr. Sivanesan , Dr.Settu, Dr. Manian , Dr. Swetha, Dr. Manikandan, Dr. 
Kiruthika , Dr. Ramesh , Dr. Kiran Josy,  Dr. Arun Kumar J, Dr. Sowmya 
Shridharan, Dr. Priyadarshni R and Dr. Sharmila Devi for their kind support all 
through my Post graduation. I  also like to thank my seniors Dr. Allwyn Yabesh, 
Dr. Prabha G, Dr. Ganesh Aravind and Dr. Appu Raj for sharing their experiences 
and guiding me through the difficult periods.  
           Special thanks to my mother Mrs. LAKSHMI R and my beloved brother 
Mr. VINOTH KUMAR K , who were solely responsible for who I am now.  
            I also place on record, my sense of gratitude to one and all, who directly or 
indirectly, have lent their hand in this project. 
     Last but not the least my heartfelt thanks to all patients who formed this study 
group and co-operated wholeheartedly. 
  
Submission author:
Assignment t it le:
Submission tit le:
File name:
File size:
Page count:
Word count:
Character count:
Submission date:
Submission ID:
Digital Receipt
This receipt acknowledges that Turnit in received your paper. Below you will f ind the receipt
inf ormation regarding your submission.
The f irst page of  your submissions is displayed below.
201311152.m.d In General Medicine…
TNMGRMU EXAMINATIONS
Dr. Dilip Kumar R dissertation
REVIEW_OF_LITERATURE.docx
2.67M
120
12,873
66,750
25-Sep-2015 04:48PM
568202726
Copyright 2015 Turnitin. All rights reserved.

LIST OF ABBREVATIONS 
 
Sl No ABBREVIATION EXPANSION 
1. ACS Acute Coronary Syndrome 
2. AMI Acute Myocardial Infarction 
3. AHA American Heart Association 
4. ACC American College of cardiology 7, 
4. cTn Cardiac Troponins 
5. CABG Coronary Artery Bypass Grafting 
6. CHF Congestive Heart Failure 
7. ECG ElectroCardioGram 
8. ESC European Society of Cardiology 
9. EF Ejection Fraction 
10. LAD Left Anterior Descending artey 
11. LCx Left Circumflex artery 
12. LCA Left Coronary Artery 
13. LBBB Left Bundle Branch Block 
14. MI Myocardial Infarction 
15. STEMI ST Elevation Myocardial Infarction 
16. NSTEMI Non ST Elevation Myocardial Infarction 
17. AWMI Anterior Wall Myocardial Infarction 
18. ASMI AnteroSeptal Myocardial Infarction 
19. ALMI AnteroLateral Myocardial Infarction 
20. IWMI Inferior Wall Myocardial Infarction 
21. RVMI Right Ventricular Myocardial Infarction 
22. PWMI Posterior Wall Myocardial Infarction 
23. STE ST Elevation 
24. UA Unstable Angina 
25. Trop Troponin 
26. TIMI Thrombolysis In Myocardial Infarction 
27. WHO World Health Organization 
28. CK Creatine Kinase 
29. S3 Third Heart Sound 
 
            
 
 
 
TABLE OF CONTENTS 
S.NO CONTENTS PAGE NO 
1. INTRODUCTION 10 
2. AIM OF THE STUDY 15 
3. REVIEW OF LITERATURE 16 
4. SUMMARY 60 
5. MATERIALS AND METHODS 62 
6. RESULTS 67 
7. DISCUSSION 94 
8. CONCLUSION 100 
9. BIBLIOGRAPHY 101 
10. ANNEXURE PROFORMA 108 
MASTER CHART 115 
KEYS TO MASTER CHART 119 
ETHICAL COMMITTEE 
CLEARANCE FORM 
120 
 10 
INTRODUCTION 
 
ACUTE CORONARY SYNDROMES : 
          Acute Coronary Syndromes (ACS) represents a broad collection of 
conditions : 
1. Acute Myocardial infarction manifested by ST Elevation MI , 
also called as Q wave MI and Non ST Elevation MI wave also 
called as non Q wave MI.  
2. Unstable Angina (UA) 
 
            As opposed to STEMI which results from complete and prolonged 
occlusion of an epicardial vessel. Notably, the clinical presentation and 
symptoms may be similar for these syndromes. 
 
          The primary goals of treatment in NSTE-ACS are to relieve and/or 
limit ischemia , prevent infarction or reinfarction, and improve outcomes. 
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DEFINITIONS : 
 
1. STEMI is diagnosed in an appropriate clinical setting with the finding 
of >= 1mm or >= 0.1cm elevation of the ST segment in at least two 
contiguous leads of an electrocardiogram (ECG) associated with cardiac 
biomarker elevation. 
2. NSTEMI/UA is diagnosed in an appropriate clinical setting when there 
is no ST segment elevation . ECG may show ST segment depression or T 
wave abnormalities, but may be normal, with (NSTEMI) or without (UA) 
myocardial necrosis demonstrated by cardiac biomarker elevation.1 
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The current universal definition for acute myocardial infarction (AMI) 
adopted by the ESC/ACF( American Cardiology Foundation ) /AHA 
WHO Task Force defines AMI as evidence of myocardial necrosis in the 
appropriate clinical setting meeting any of the following criteria2: 
elevated cardiac biomarkers, preferably serum troponin, with minimum 
one value of the biomarker  >99% of the upper reference limit (URL) 
with one of the following: 
1. Ischemic symptoms 
2. New ischemic ECG changes (new changes in the ST-T segment or 
evidence of new left bundle branch block) 
3. New pathologic Q waves 
4. Evidence of new infarction by cardiac imaging 
5. Intracoronary thrombus noted on angiography or autopsy 
 
Post PCI – greater than 3 times normal elevation of cardiac biomarkers 
signify PCI related myocardial infarction. 
 
Post  CABG – greater than 5 times the normal elevation of cardiac 
biomarkers with new Q waves/ LBBB, graft/native coronary artery 
occlusion , or infarction by cardiac imaging signify CABG related 
myocardial infarction.  
 
 13 
EPIDEMIOLOGY : 
 
ACS represents almost 1.6 million hospitalizations each year. This 
syndrome requires early diagnosis and aggressive management to 
minimize myocardial damage . Despite maximal medical therapy , at the 
end of 1 year , those patients diagnosed wih NSTEMI and treated for it 
are still at a risk of death (5.91%), risk of  recurrent myocardial infarction 
(10.87%)  and recurrent need for a revascularization (49-61%). It is 
important , in fact extremely necessary to note that even though the short 
term mortality for ST Elevation MI is higher when compared to Non ST 
Elevation MI , the long term mortality is still the same.  
 
There are a lot of tools necessary to assess ACS . Our discussion will 
pertain to STEMI , and it has a Very high short term and even high long 
term mortality as well. All tools including Physical and laboratory tools 
are essential to make a diagnosis of STEMI , but this is to emphasize the 
use of TIMI score ( Thrombolysis In Myocardial Infarction – TIMI ) for 
STEMI to assess the values of Cardiac Biomarkers and Ejection fraction ( 
both of which in turn are significant predictors of infarct size – 
morbidity/mortality in short and long term).  
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TIMI score for STEMI uses simple bedside data along wit ECG to 
determine the 30 day mortality rate , but again we emphasize the use of 
the score to predict Troponin T biomarker and Ejection fraction , so that 
it can be used to predict those values at the time of admission itself . ( one 
step ahead ) 
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AIMS AND OBJECTIVES 
AIMS : 
To assess the TIMI score for acute STEMI and its relationship with 
Quantitative Troponin T and LV Ejection Fraction . 
 
OBJECTIVES : 
1. To assess the relationship between TIMI score for acute STEMI 
and Single Quantitative Troponin T at 12 hours following 
admission.  
2. To assess the relationship between TIMI score for acute STEMI 
and EF < 40% at 48 hours post admission.  
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REVIEW OF LITERATURE 
 
             ST-segment elevation myocardial infarction (STEMI) represents 
a pathophysiologic process among the acute coronary syndromes (ACS) 
that is different from that of and non–ST-segment elevation myocardial 
infarction ( NSTEMI) and Unstable angina . (UA) 
• The therapeutic paradigm for STEMI mandates a rapid decision 
regarding reperfusion. 
• Time to reperfusion (i.e., “door to balloon” or “door to needle”)is an 
important component of these therapies and has become a major 
benchmark for institutional quality of cardiovascular care. 
 
Definition 
• Pathologic definition: cardiac myocyte cell death, usually due to 
prolonged myocardial ischemia.  
• Clinical definition of myocardial infarction (MI) that has been 
established by the WHO/AHA/ESC/ACC requires the rise and/or fall of 
cardiac biomarkers for myocardial necrosis in addition to one of the 
following1: 
1. Ischemic symptoms 
2. Electrocardiogram (ECG) changes consistent with ischemia or 3. 
pathologic Q waves 
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4. Confirmation of infarction on imaging 
5. Autopsy evidence of myocardial cell death is also sufficient. 
• STEMI can be differentiated clinically from NSTEMI by the presence 
of changes in ECG specific to them (i.e., ST elevation, new left bundle 
branch block [LBBB]). 
 
Classification 
• The designation of STEMI includes not only classic ST elevation but 
also new LBBB. 
• The descriptors “Q wave” and “non-Q wave MI” have lost favor 
because the majority of STEMIs are Q-wave MIs. 
• A consensus statement by the ACC/AHA/ESC/WHF published in 2012 
refines and broadens the classification of MI and includes categories 
based on procedure associated MIs, demand ischemia, and sudden cardiac 
death. 
 
Epidemiology 
• An estimated 50,00,000 patients in India will suffer a STEMI annually. 
• A significant proportion of these patients will die from sudden cardiac 
death due to ventricular arrhythmia prior to arriving at the hospital. 
• The success of the medical community’s concerted efforts has led to a 
26% reduction in mortality since 1990. 
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• Overall survival rates across the majority of good Indian Centres are 
>90%. 
• However, the death rate remains high among the subgroup of patients 
who develop cardiogenic shock or other mechanical complications of 
STEMI, with mortality in excess of 50%. 
 
Etiology 
• Any condition or event that results in interruption of coronary flow 
sufficient to produce cell death in the myocardium can lead to MI. 
• Usually can result from an acute change in the preexisting coronary 
plaque that leads to thrombotic mediators getting activated and 
subsequent clot formation with obstruction to blood flow. 
• Although there is a spectrum in terms of the degree of artery obstruction 
and cell death, it is the significant or complete coronary occlusion, which 
leads to STEMI. 
• Other conditions that can lead to STEMI include 
1. Severe coronary vasospasm  
2. Embolization 
3. Spontaneous coronary dissection 
These conditions should be considered in the patient whose clinical 
findings suggest a process other than acute plaque rupture. 
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Pathophysiology 
• Most commonly due to coronary artery occlusion by thrombus, which 
often forms in situ at the site of an atheromatous plaque. 
• The mechanisms involved vary by age and gender. 
1. Plaque rupture causes the majority of events in men and older women. 
2. Plaque erosion is a more common mechanism in younger women. 
• Involves mild-to-moderate immature plaques (i.e., those that do not 
significantly impede coronary flow at baseline) with thin fibrous caps and 
lipid-rich cores that rupture in the acute setting of inflammation, shear 
forces, and local rheologic 
factors. 
• This initiates a sequence of platelet aggregation, fibrin deposition, and 
vasoconstriction, forming the classic fibrin-rich red thrombus, which 
completely occludes the involved artery, predisposing to STEMI. 
• Left untreated, the mortality rate of uncomplicated STEMI can exceed 
30%. 
• Mechanical complications are more common when a STEMI is 
untreated. 
• In addition, the heart undergoes the detrimental process of remodeling. 
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ATHEROSCLEROSIS:  
 
 
 
1, Normal artery.  
 2.Endothelial cells , activated by 
risk factors which may include hyperlipoproteinaemia, usually express 
adhesion as well as chemoattractant molecules that recruit inflammatory 
leucocytes such as monocytes and T lymphocytes.  Extracellular lipid 
begins to accumulate in intima at this stage. 3, Evolution to fibrofatty 
stage. Monocytes recruited to artery wall become macrophages and 
express scavenger receptors that bind modified lipoproteins. 
Macrophages become lipid-laden foam cells by engulfing modified 
lipoproteins. Leucocytes and resident vascular wall cells can secrete 
inflammatory cytokines and growth factors that amplify leucocyte 
recruitment and cause smooth muscle cell migration and proliferation. 4, 
As lesion progresses, inflammatory mediators cause expression of tissue 
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factor, a potent pro-coagulant, and of matrix-degrading proteinases that 
weaken fibrous cap of plaque. If fibrous cap ruptures at point of 
weakening, coagulation factors in blood can gain access to thrombogenic, 
tissue factor-containing lipid core, causing thrombosis on non-occlusive 
atherosclerotic plaque. If balance between prothrombotic and fibrinolytic 
mechanisms prevailing at that particular region and at that particular 
time is unfavourable, occlusive thrombus causing ACS may result. 6, 
When thrombus resorbs, products associated with thrombosis such as 
thrombin and mediators released from degranulating platelets, can cause 
healing response, leading to increased collagen accumulation and smooth 
muscle cell growth. In this manner, the fibrofatty lesion can evolve into 
an advanced fibrous and often calcified plaque, one that may cause 
significant stenosis, and produce symptoms of stable angina pectoris. 7, 
In some cases, occlusive thrombi arise not from fracture of fibrous cap 
but from superficial erosion of endothelial layer. Resulting mural 
thrombus, again dependent on local prothrombotic and fibrinolytic 
balance, can cause acute myocardial infarction. 
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The pathophysiology of atherosclerosis with respect to lesion 
development, progression and destabilization. Biomarkers with distinct 
pathophysiological profile can be used to assess disease activity. 
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“Atherothrombosis : A variable mix of chronic atherosclerosis and acute 
thrombosis. Cross-sectioned arterial bifurcation illustrating a collagen-
rich (blue-stained) plaque in the circumflex branch (left), and a lipid-rich 
and ruptured plaque with a non-occlusive thrombus superimposed in the 
obtuse branch (right). Ca, calcification; T, thrombus; C, contrast in the 
lumen.” 
 
FEATURES OF A VULNERABLE PLAQUE : 
 
1. Large lipid-rich core (> 30–40% of plaque) 
2. Fibrous cap covering the lipid-rich core 
3. Thin (thickness < 100 μm) 
4. Many macrophages (inflammation) 
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5. Few smooth muscle cells (apoptosis) 
6. Outward remodelling preserving the lumen 
7. Neovascularization from vasa vasorum 
8. Adventitial/perivascular inflammation 
 
 
 
Vulnerable plaque. Cross-section of a coronary artery containing a plaque 
assumed to be rupture-prone, consisting of a relatively large lipid-rich 
core covered by a thin 
and fragile fibrous cap. Trichrome stain, rendering collagen blue and lipid 
colourless. 
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RUPTURED PLAQUE : 
 
 
 
 
Plaque rupture. Cross-sectioned coronary artery containing a lipid-rich 
atherosclerotic plaque with occlusive thrombosis superimposed. The 
fibrous cap covering the lipid-rich core is ruptured (between arrows) 
exposing the thrombogenic core to the blood in the lumen. Atheromatous 
plaque content is displaced through the gap in the cap into the lumen 
(cholesterol crystals at asterisk), clearly indicating 
the sequence of events: plaque rupture preceded thrombus 
formation. Trichrome stain, rendering luminal thrombus and 
intraplaque haemorrhage red and collagen blue. 
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Plaque vulnerability, rupture and thrombosis. Lipid accumulation, 
cap thinning, macrophage infiltration, and local loss of smooth muscle 
cells destabilize plaques, making them vulnerable to rupture. It is 
unknown whether rupture of a vulnerable plaque 
is a random (spontaneous) or triggered event. The thrombotic response to 
plaque rupture is dynamic and depends on local 
(e.g. exposed substrate and shear forces) as well as systemic factors (e.g. 
platelets, coagulation and fibrinolysis). 
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Thrombotic burden. Thrombosed coronary artery cut open longitudinally, 
illustrating a voluminous erythrocyte-rich stagnation  thrombosis (dark 
black on screen) that has developed secondarily to blood stagnation 
caused by an occlusive platelet-rich thrombus (white) formed on top of a 
severely stenotic and ruptured plaque (arrow). The white material in the 
lumen is contrast medium injected postmortem. LM, left main stem; 
LAD, left anterior descending 
coronary artery; Cx, circumflex branch; 1st; first diagonal branch. 
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DIAGNOSIS 
 
Clinical Presentation 
• Patients presenting with a suspected ACS should undergo rapid 
evaluation. 
• A focused history, physical, and ECG interpretation should be 
performed within 10 minutes of arrival in the emergency department to 
allow for timely reperfusion 
when appropriate. 
 
 
History 
• Quickly acquire adequate historical information in the setting of 
diagnostic ECG changes to initiate treatment and mobilize, when 
appropriate, the team for percutaneous revascularization. 
• Chest discomfort is the most common symptom. 
Typically progressive, substernal to left-sided, and often similar in quality 
to typical angina. 
Usually intense and prolonged, lasting more than 20 to 30 minutes. 
Unlike UA/NSTEMI, rest and nitroglycerin usually do not provide 
significant relief. 
• Review absolute and relative contraindications to thrombolytic therapy 
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(Table-1 ) which are intended as recommendation for clinical decision 
making, but other contraindications may be present and decisions must be 
made on a case-by-case 
basis.4 
• Review issues regarding primary percutaneous coronary intervention 
(PCI), including allergy to contrast agents, issues relating to vascular 
access (peripheral vessel disease or previous peripheral revascularization 
procedures), previous cardiac catheterizations and complications, history 
of renal dysfunction,  central nervous system disease, pregnancy, or 
bleeding diathesis. 
• Traditional risk factors are weak predictors of the likelihood of acute 
infarction as the presenting etiology. 
 
TABLE -1 : 
The following Table – 1 shows the contraindications to thrombolysis . 
This is important since the patients we select must be thrombolysis 
eligible ! 
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PHYSICAL EXAMINATION : 
 
• Important in determining other potential sources of chest pain, assessing 
prognosis, and establishing a baseline that will aid in the early 
recognition of complications. 
• The goal is to determine hemodynamic stability, the presence of 
cardiogenic pulmonary edema, or mechanical complications of MI 
(papillary muscle dysfunction, free wall rupture, and ventricular septal 
defect [VSD]) and exclude other etiologies of acute chest discomfort. 
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• Should include assessment of vital signs and oxygenation with bilateral 
blood pressures as well as jugular venous pressure; pulmonary 
examination for pulmonary edema; cardiac examination for arrhythmia, 
murmurs, gallops, or friction rub; vascular examination for evidence of 
peripheral vascular disease and pulse deficits; and neurologic 
examination (especially prior  to the administration of thrombolytics). 
 
Differential Diagnosis 
• The inherent risks of both thrombolytic therapy and primary PCI 
mandate that alternative diagnoses be considered in patients with chest 
pain. 
• In particular, administration of thrombolytic agents in certain 
conditions, such as aortic dissection, may lead to death. 
• In the situation when the diagnosis is uncertain, primary PCI offers a 
distinct advantage as the initial reperfusion strategy. 
• Differential diagnosis of chest pain: 
Life-threatening: aortic dissection, pulmonary embolus, perforated ulcer, 
tension pneumothorax, and Boerhaave syndrome (esophageal rupture 
with mediastinitis). 
 
Other cardiac and noncardiac causes: pericarditis, myocarditis, 
vasospastic angina, gastroesophageal reflux disease, esophageal spasm, 
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costochondritis, pleurisy, peptic ulcer disease, panic attack, biliary or 
pancreatic pain, cervical disc or neuropathic pain, and somatization and 
psychogenic pain disorder. 
 
• Differential diagnosis of ST elevation on ECG:  
1. pericarditis  
2. pulmonary embolism 
3. aortic dissection with coronary artery involvement 
4. normal variant 
5. early repolarization 
6. left ventricular (LV) hypertrophy with strain 
7. Brugada syndrome 
8. Myocarditis 
9. Hyperkalemia 
10. Others include HOCM, Bundle branch blocks, Prinzmetal Angina 
etc. 
 
DIAGNOSTIC TESTS : 
 
• The ECG should be performed and interpreted within 10 minutes of 
presentation.  
• The ECG should be repeated every 20 to 30 minutes for up to 4 hours if 
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the patient has persistent symptoms when there is clinical suspicion for 
AMI, but the ECG is nondiagnostic. 
• Hyperacute T waves, seen as either tall or deeply inverted T waves, may 
be an early sign of AMI that warrants close monitoring. 
• Recognition of the limitations of the ECG in AMI is also important as 
up to 10% of patients with an acute STEMI may have a normal ECG as 
certain myocardial segments of the left ventricle are not adequately 
represented, particularly the 
posterior and lateral walls, which are supplied by the left circumflex 
artery. 
 
 
ECG criteria for diagnosis of STEMI: 
 
≥1 mm (0.1 mV) of ST-segment elevation (STE) in two or more 
contiguous limb leads, or 
2 mm in two contiguous precordial leads for men and 1.5 mm in two 
precordial leads for women 
• The location and degree of STE determine the occluded anatomy and 
prognosis and can alert the physician to potential complications of MI. 
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• Special considerations: 
The presence of a new LBBB in the setting of acute chest symptoms 
suggests occlusion of the proximal left anterior descending (LAD). 
Patients presenting with this finding should be managed in the same 
manner as the patient with a classic STEMI. 
 
In the setting of an old LBBB or an RV-paced rhythm, an acute injury 
pattern may be supported by the Sgarbossa criteria5: 
1. STE ≥1 mm in the presence of a positive QRS complex (ST elevation 
is concordant with QRS). 
2. ST-segment depression ≥1 mm in lead V1, V2, or V3. 
3. STE ≥5 mm in the presence of a negative QRS complex (ST elevation 
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is discordant with QRS). 
 
Example of a STEMI – ECG shows extensive Anterolateral MI with 
reciprocal changes in inferior leads.  
 
Posterior MI is an entity that is often unrecognized and should be 
suspected by the clinician in the setting of inferior or lateral wall infarct. 
Isolated posterior MI is uncommon. 
The “reverse mirror test” is useful to demonstrate that the ST-segment 
depression in leads V1 to V3 is actually ST elevations in the posterior 
wall. 
The prominent R waves in these leads represent posterior Q waves. 
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Example of a Inferoposterior MI in RCA territory . 
 
Inferoposterior and posterolateral MIs typically involve the right 
coronary artery (RCA) or obtuse marginal branch of the left circumflex 
coronary artery (LCx), respectively. 
Posterior leads (V7 to V9) may be placed to help distinguish posterior MI 
from anterior ischemia or reciprocal depression in all patients presenting 
with ST depression in leads V1 to V3. 
 
ST elevation in the inferior leads should always prompt a right-sided 
ECG to assess for right ventricular (RV) infarction. ST elevation in leads 
V3R and V4R suggests RV involvement. 
 
RV infarction should also be suspected on a standard 12-lead ECG when 
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there is STE in V1 along with changes indicating inferior MI. 
The finding of ST elevation in lead III greater than in lead II also 
suggests RV infarct. 
Proximal RCA lesions typically involve the RV, as RV marginal 
branches arise early from the RCA. 
 
 
Although the principle for the revascularization of RV infarct is the same 
for other STEMIs, other aspects of treatment are unique, including 
maintenance of adequate preload and the cautious use of nitrate and β-
blocker therapy to avoid hypotension. ST segments in pericarditis 
normalize before there is T-wave inversion, whereas the T waves invert 
before ST normalization in STEMI. 
 
STE in pericarditis is typically diffuse, does not correlate with a 
particular vascular territory, and does not exhibit reciprocal ST 
depressions. 
PR-segment depression in acute pericarditis may also differentiate these 
two conditions.  Pericarditis may present later in the course of AMI and 
should be differentiated from recurrent ischemia or stent thrombosis. 
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Imaging 
• A standard portable chest radiograph (CXR) should be included in the 
initial evaluation protocol. 
Pulmonary edema on CXR has important prognostic and therapeutic 
implications. 
Should be reviewed for mediastinal widening, suggesting acute aortic 
dissection, prior to initiating thrombolytic therapy. 
If clinical suspicion is high; however, normal mediastinal width does not 
exclude dissection. 
• The evaluation of a patient with chest pain in the setting of a 
nondiagnostic ECG (i.e., LBBB of unknown duration, paced rhythm) 
may be aided by an echocardiogram. Segmental wall motion 
abnormalities suggest myocardial ischemia or infarction, assuming no 
baseline wall motion abnormalities and can help localize the territory at 
risk. 
 
Laboratories 
• Cardiac biomarkers are important in the diagnosis and prognosis of 
STEMI but have a limited role in the initial decision-making process. 
Markers used for determining the presence of myocardial necrosis—
including creatine kinase MB, troponin, and myoglobin.  
• Standard laboratory evaluation should include a basic metabolic profile, 
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magnesium level, liver function, lipid profile, complete blood count, and 
coagulation studies.  
The center of our article TROPONIN T biomarker has been discussed in 
detail in the coming review.  
 
Risk Stratification in ST-segment elevation 
myocardial infarction : 
 
Whereas risk factors for the development of atherothrombosis 
provide insights into disease mechanisms and the opportunity for primary 
and secondary prevention therapy, analysis of the risk for adverse 
outcome after presentation with ST-segment elevations is critically 
important in guiding management and therapeutic decisions. 
 
 
Analysis usually uses a combination of clinical, ECG and biochemical 
parameters. Five rather simple baseline parameters can be used to predict 
more than 90% of the 30-day mortality: age, systolic blood pressure, 
Killip class, heart rate and infarct localization. 
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Killip class 
 
The haemodynamic impact of the evolving myocardial infarction is 
clinically evident by the symptoms of shock.The Killip classification is 
widely used and linked to outcome. Killip class IV (‘cardiogenic shock’) 
is found in about 5% of AMI patients and is associated with extremely 
high mortality. 
 
Infarct location 
 
The prognosis of myocardial infarction is related to the extent of 
myocardium at risk and, related to this, to the site of coronary occlusion. 
The ECG reflects the infarct location (Table 12.5). Patients with main 
stem occlusion only rarely reach the hospital for reperfusion therapy. 
Occlusion of the proximal left anterior descending coronary artery 
proximal to the first septal branch is associ ated with high early and late 
mortality (‘widow-maker’). Large inferior myocardial infarctions as a 
result of occlusion of a dominant right coronary artery are also a high 
risk, particularly when the right ventricle is involved. Other locations, 
such as apical (distal left anterior descending), lateral (diagonal branch), 
or small inferior infarctions (distal right or circumflex), show ST-segment 
elevations in only a few leads and have a better outcome. Strictly 
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posterior myocardial infarctions (marginal branch of left circumflex) may 
escape routine ECG leads or only be evident through ST depression in V1 
to V4, but usually have a good outcome. 
 
Acute myocardial infarction based on electrocardiographic entry criteria 
with angiographic correlation. 
 
ECG criteria 
 
The ECG allows the rough location of the infarct artery 
and identification of the extent of the territory at risk. The development of 
a bundle branch block or atrioventricular block in anterior myocardial 
infarctions suggests involvement of a proximal septal artery and is 
associated with increased mortality. Atrioventricular blocks in inferior 
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myocardial infarctions are frequent and mostly transient. 
Biomarkers on presentation 
 
Blood sampling for serum markers must be routinely performed 
in the acute phase, but one should not wait for the results to initiate 
reperfusion treatment. The finding of elevated markers of necrosis may 
sometimes be helpful in deciding to give reperfusion therapy (e.g. in 
patients with left bundle branch block), but should retard decisionmaking. 
Elevation of markers of necrosis (troponin) on 
arrival in hospital is associated with adverse outcome [167]. 
 
 
Multivariate model of 30-day mortality according to GUSTO I trial. 
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• Multiple proven risk assessment tools utilize information obtained 
during the history, physical examination, and diagnostic evaluation, 
which provide an estimate of 30-day mortality following AMI. 
• The Killip classification uses bedside physical examination findings 
including an 
S3 gallop, pulmonary congestion, and cardiogenic shock6 
• The Forrester classification uses hemodynamic monitoring of cardiac 
index and pulmonary capillary wedge pressure (PCWP)7 
• The most recent prognostic system, the thrombolysis in myocardial 
infarction (TIMI) risk score , combines history and examination findings 
in patients with STEMI treated with thrombolytics.8 
• This is a different risk score than that used for risk stratification in the 
setting of UA/NSTEMI. 
 
KILLIP SCORE FOR ACUTE MI : 
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FORRESTER CLASSIFICATION SYSTEM FOR ACUTE MI : 
 
This System uses PCWP as mainstay : 
 
 
 
     But we can use a simplified forrester class : (clinically ) 
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THE THROMBOLYSIS IN MYOCARDIAL INFARCTION  (TIMI) 
SCORE FOR ST ELEVATION MYOCARDIAL INFARCTION 
(STEMI ) : 
 
 
 
Max points – 14 
Minimum Points – 0 
Entry criteria:  
1. Chest pain for more than 30 minutes. 
2. ST elevation. 
3. Symptom onset less than 6 hours. 
4. Fibrinolytic eligible. 
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These were important In our discussion and analysis as they form the 
criteria for inclusion and if not the subjrcts are excluded.  
 
30 day mortality rate based on TIMI score :  
 
 
 It is important to note that cardiac biomarkers especially the cardiac 
troponins and also the Ejection Fraction (EF) are not included in the 
scoring system.  
 Since the Scoring system provides indirect (Qualitative ) ways of 
assessing them , we wanted to know whether there was any quantitative 
relationship if at all to provide resource limited clinicians a great 
information about the predictions .  
For example low SBP, tachycardia and Killip 2,3,4 of TIMI score may be 
a clue towards Low EF.  
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The same may also predict large infarct and a high troponin levels at 72 
hrs .  
Our aim is to translate such data into a quantitative one that can be used 
by all.  
 
The GRACE risk score for ACS ( not STEMI alone ) : 
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GRACE score calculates in hospital and 180 day mortality rate.  
It also uses other data like  
1. Enzyme elevation 
2. PCI done/not 
3. S. Creatinine  
4. ST depression  
These are not used in the TIMI score.  
The data is as follows according to the literature : 
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CARDIAC BIOMARKERS :  
Markers of myocardial necrosis : 
Pathohistological studies in patients with unstable angina have disclosed 
focal cell necroses in the myocardium distal to the culprit artery. These 
were attributed to repetitive thrombus embolization 10,11. Focal cell 
necroses, or so-called minor myocardial injuries, are very infrequently 
detectable by routine creatine kinase (CK) and CK-MB measurements. 
Even improved test systems for the quantitative determination of CK-MB 
based on immunological determination, which are superior to enzyme 
activity measurements, did not substantially increase the sensitivity for 
the detection of minor myocardial injury. Myoglobin is a marker which 
rises 
earlier than CK-MB in AMI but has similar limitations with respect to 
specificity.  
These biochemical limitations of CK-MB and myoglobin measurements 
for the detection of minor myocardial 
injury have been overcome by the introduction of troponin measurements 
.In the early 1990s, the cardiac isoforms of troponin T and troponin I 
were introduced into clinical practice. The troponin complex is formed by 
three distinct structural proteins 
(troponins I, C and T) and is located on the thin filament of the contractile 
apparatus in both skeletal and cardiac muscle tissue regulating the 
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calcium-dependent interaction of myosin and actin. Cardiac isoforms for 
all three troponins, however, are encoded each by different genes and can 
be distinguished by monoclonal antibodies recognizing the amino acid 
sequence distinct for the cardiac isoform12. However, only the cardiac 
isoforms of troponin T and troponin I are exclusively expressed in cardiac 
myocytes.  
Accordingly, the detection of cardiac troponin T and troponin I is highly 
specific for myocardial damage, attributing these markers the role of a 
new gold standard. In conditions of ‘false-positive’ elevated CK-MB, 
such as skeletal muscle trauma, troponins will clarify any cardiac 
involvement. 
In patients with a myocardial infarction, a first rise of troponins in  
peripheral blood can be observed as early as 3–4 hours because of its 
release from a cytosolic pool, followed by a prolonged appearance of up 
to 2 weeks related to continuous proteolysis of the contractile apparatus 
in the necrotic myocardium. The high proportional rise of troponins, 
relative to the low plasma troponin concentrations in healthy controls, 
allows the detection of myocardial damage in about one-third of patients 
presenting with unstable angina even without elevated CK-MB13-21. 
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Important biomarkers used in clinical practice and their rise and fall 
Troponins for risk stratification 
Troponin T molecule is shown below : 
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It has been demonstrated in numerous clinical trials that troponin T and 
troponin I are strongly associated with increased risk both in the acute 
phase of hospitalization and during long-term follow-up. In the first 
report on troponin T in a small cohort of patients with 
unstable angina, it was demonstrated that the risk of death and 
myocardial infarction during hospitalization was increased even in the 
presence of antiplatelet therapy with aspirin and heparin 19. In a substudy 
of the FRISC (Fragmin during InStability in Coronary artery disease) trial 
the prognostic value was shown to correlate with the absolute 
concentrations of troponin T over a 5-month period 19. The peak value 
during the first 24 hours provided the best independent prognostic 
information and the absence of troponin T was superior to CK-MB for 
identification of the low-risk group 22. Furthermore, the combination of 
the troponin T test with a predischarge exercise test represents an 
excellent risk assessment for 
unstable coronary disease23. During the 5-month follow-up, death and 
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myocardial infarction occurred at a rate of only 1%, if both the troponin 
test and the predischarge exercise test were normal, whereas the event 
rate was as high as 50% when both tests were abnormal. 
Moreover, the prognostic potential of troponin T in the entire spectrum of 
patients with ACS, including myocardial infarctions, was evaluated in a 
substudy of the GUSTO (Global Use of Strategies To Open occluded 
coronary arteries) IIA trial24. A single measurement within 2 hours after 
admission was highly predictive of 30-day mortality and other major 
complications. The prognostic value was independent of ECG findings 
and was superior 
to CK-MB measurements. 
For elevations of cardiac troponin I, a similar prognostic impact was 
evidenced as for troponin T elevations. In the TIMI IIIB trial including 
patients with unstable angina and non-Q-wave myocardial infarction, the 
mortality rate was closely related to troponin I levels reaching 7.5% after 
42 days follow-up in patients with the highest 
troponin I values20. 
 
“IT HAS NOT BEEN PROVEN IN ANY TRIAL THAT ONE 
TROPONIN IS SUPERIOR TO ANOTHER “ 
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Currently, the diagnostic threshold for troponin T may be maintained 
between 0.06 and 0.10 μg/l, depending on the local laboratory 
performance. 
 
CAUSES OF ELEVATED TROPONINS OTHER THAN 
MYOCARDIAL INFARCTION : 
 
1. Myocarditis 
2. Pericarditis 
3. Cardiac contusion /trauma 
4. Aortic dissection 
5. Endocarditis 
6. Cardiac Surgery 
7. Pulmonary Embolism 
8. Stroke 
9. CPR 
10. Defibrillation 
11. Chronic Severe Heart Failure 
12. Cardiac Arrhythmias 
13. Sepsis 
14. Renal failure 
15. Burns 
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16. HOCM 
17. Takatsubo cardiomyopathy 
18. Extreme exertion 
19. Post Cardiac Surgery 
20. Infiltrative diseases like amyloidosis 
21. Transplant Vasculopathy 
22. Post PCI 
23. Post CABG 
24. Medications – Doxorubicin, Trastuzumab , Snake venom 
25. Critical Illness 
 
 
Note that the troponin elevation In unstable angina is very minimal to be 
detected in routine testing (current lab standards ). So by definition UA 
does not cause DETECTABLE troponin elevation rather than it does not 
mean that they donot rise.  
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LV EF as  a Predict0r of Increased/Higher Risk : 
The risk of mortality that was associated with a decreased LV-EF after 
Myocardial Infarction and especially after a ST Elevation MI has been 
recognized for long .An LV Ejection fraction of < 40% was found to be 
an independent mortality predict0r in the MPR group ar0und the 
1980’s.26 During the 1990’s, in the CAMI study- Canadian Assessment of 
MI , the odds ratio 1 year mortality after MI was 9.28 for patients with 
LV Ejection Fraction ≤ 40% compared with the patients with a LV 
Ejection Fraction > 50%, 2.64 for patients with LV Ejection Fraction of  
30–40%, and however the risk was not at all significantly elevated in 
patients with LV Ejection fraction of 40–50%27. Thus, in a overview there 
tends to be a rough LV Ejection Fraction threshold of ~40% for an 
elevated risk post-MI . 
More latest studies have confirmed this. In the ATRAMI study – 
Aut0nomic T0ne and Reflexes After Myocardial Infarction which has 
enr0lled 1286 patients with recent MI, patients with LV-EF of 35–50% 
had a relative risk of 2.48 for  mortality related to cardiac component 
compared with patients with LVEF > 50%, whereas in patients with 
LVEF < 35%, the relative risk was 7.3.28 
“Left ventricular ejection fraction, thus is a strong predictor of arrhythmic 
death. Direct evidence for this has been provided by the randomized trials 
 57 
of ICD implantation for primary prevention in patients with low LV-EF. 
For instance, the Multicenter Automatic Defibrillator Implantation Trial 
II (MADIT-II) randomized 1243 patients with previous MI and LV-EF 
≤30% to ICD or conventional medical therapy29.” During average period 
of follow-up of 20 months, the mortality rate was significantly lower in 
the defibrillator group (14.2 vs. 19.8%).  
“Similar findings were provided by the Sudden Cardiac Death in Heart 
Failure Trial (SCD-HeFT), which randomized 2531 patients with NYHA 
class II or III heart failure and LVEF ≤ 35% to placebo, amiodarone, or a 
single-lead ICD in addition to conventional therapy30. The cause of heart 
failure was ischaemic in 52%. ICD therapy was associated with a 
decreased risk of death of 23% without interaction with the heart failure 
cause. Since the ICD affects only arrhythmic death, this mortality 
reduction is attributed to a reduction in Sudden Cardiac Death.  
The ICD trials were particularly designed for Primary prevention to 
actually evaluate the importance of ICD in people with high risk , defined 
by decreases LV Ejection fraction, and not to look for various variables 
including  LV Ejection Fraction as risk stratifiers. “Thus, they sh0w that a 
reduced LV Ejection Fraction is associated with an elevated SCD risk and 
that Implantable cardioverter Defibrillator therapy improves survival, but 
usually don’t  establish LV-EF as optimal risk stratification variable.” 
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The increased Sudden Cardiac Death risk 0f patients with reduced LV-EF 
is confirmed by  studies. Thus, in a multivariable analysis of the 
Multicenter Unsustained Tachycardia Trial (MUSTT), reduced LV-EF 
was associated with increased risk for arrhythmic death or cardiac 
arrest.31 
“Recent studies have replicated these findings: In the ISAR-Risk, which 
studied 2443 acute Myocardial Infarction survivors, an LVEF ≤ 30% 
predicted all-cause mortality, cardiac mortality, and Sudden Cardiac 
Death at 5 years32.”  Sensitivity and specificity for Sudden Cardiac Death  
prediction were 22.1 and 95.4%, respectively. However, the positive 
predictive accuracy was only 12.0%. The Risk Estimation Following 
Infarction, Noninvasive Evaluation (REFINE) cohort study evaluated the 
utility of a combined assessment of  the different risk stratifiers in 332 
patients early after Myocardial Infarction with LV-EF < 50% for 
prediction of cardiac death or resuscitated cardiac arrest.33” A reduced 
LV-EF (≤30%) was a good predictor for cardiac death or resuscitated 
cardiac arrest (hazard ratio 3.3, P = 0.005). However, the area under the 
receiver-operating characteristic curve was moderate (0.62) indicating the 
limitations of LV-EF as a sole predictor.” 
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“Thus in short , the LV Ejection Fraction < 40% can be taken as a 
independent risk factor for mortality but with a pinch of salt. “ 
Since TIMI score equates to mortality data at 30 days and also uses 
variables that predict Low EF , our goal is to find out if there are any 
quantitative relationship between both.  
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SUMMARY 
   ACS is a multifactorial disease of utmost emergency. The subtype ST 
Elevation MI is a cardiac/medical emergency and prompt action is 
essential as it has a very high in hospital and equally high long term 
morbidity/mortality. Risk Stratification forms the crux of management 
protocol since one has to know which patients are likely to develop 
serious and essentially life threatening complications.  
   There are lot of individual variables like Troponin T quantitative , Age , 
Angiographic localization ,Ejection fraction etc and there are scores ( 
Forrester, TIMI score , GRACE score ) which bring one or more 
individual variables together into the scoring system to form the risk 
assessement strategy. 
   Of note , the TIMI score is the one which is entirely clinical and 
bedside ( except for the ECG – the only investigation , which in turn can 
also be done bedside ) .  
   The TIMI score for STEMI traditionally calculates the 30 day mortality 
rate and it also uses clinical data that are indirect markers of infarct size 
and Cardiac function.  
    So, Our goal is to find out any quantal relationship existing between 
TIMI score for STEMI and these individual investigation related 
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variables and of note the TROPONIN T and LV EJECTION FRACTION 
<40%. In other wors our goal is to find out the relationship between 
bedside data and laboratory parameters , but rather quantitatively. 
    These relations if existing and if delineated , can provide a ital. clue to 
the clinician to determine the trop t level and patients with LV-EF <40% 
at the time of admission itself !! 
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MATERIALS & METHODS 
 
STUDY POPULATION : 
       New patients admitted with ACS- Acute ST Elevation Myocardial 
Infarction in the casualty of Govt Kilpauk Medical College and Hospital , 
Chennai.  
STUDY TYPE : 
      Cross sectional Study. (Descriptive) 
STUDY PERIOD : 
      Data collection done for a period of 6 months between Dec 2014 to 
May 2015.(over a period of 6 months ) 
PLACE OF STUDY : 
     Govt .Kilpauk Medical College and Hospital  
Sample Size : 50  
 DEFINITION : 
    We use WHO citeria to define STEMI : 
1. Evidence of ST elevation in ECG (0.1 mm ST elevation In atleast 2 
contiguous leads) 
2. Ischemic type of chest pain . ( central – 
compressing/crushing/burning type of pain with or without 
radiation to Left or both shoulders/ arms / hands , jaw forehead etc) 
3. Rise and fall of cardiac markers .  
 63 
Supporting evidence – Echocardiographic evidence of new regional wall 
motion abnormalities, Q waves in ECG and/or angiographic evidence of 
vessel obstruction ) .  
(1) is a must with at least 1 of the other criteria with atleast one 
supporting evidence – chosen by us for convenience of this study .   
ENTRY CRITERIA : (for a patient to be eligibile for TIMI score 
calculation) 
1. Chest pain for more than 30 minutes. 
2. ST elevation. 
3. Symptom onset less than 6 hours. 
4. Fibrinolytic eligible. 
INCLUSION CRITERIA : 
    All new/fresh patients in the age group > 18 years presenting 
with acute ST Elevation Myocardial Infarction meeting the entry 
definition / entry criteria and getting admitted in Govt. Kilpauk 
Medical College and hospital . 
EXCLUSION CRITERIA : 
1. Age < 18 years 
2. Prior History/ records of ACS . 
3. Prior History of PCI/CABG 
4. Evolved MI 
5. NSTEMI/UA 
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6. Patients with history /records suggestive of heart failure. 
7. Patients with history /records suggestive of CKD 
8. Patients with history / records suggestive of or with new evidence 
of Cardiomyopathies. 
9. Severe burns  
10. Severe Sepsis  
11. Suspected cardiac trauma  
12. Suspected aortic dissection 
13. Suspected myocarditis/pericarditis 
14. Post Cardiac Transplantation.  
15. Symptom duration > 6 hours  
16. Chest pain < 30 minutes  
17. Fibrinolytic ineligible or patients with contraindications to 
fibrinolysis.  
18. Patients who are not willing to participate in the study or from 
whom we cannot obtain consent. 
METHODOLOGY : 
1. The data of each patient will be collected in a specific proforma 
(ANNEXURE 2) which includes patient’s name , age, sex, 
demographic details , presenting complaints, risk factors and all the 
clinical data.  
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2. Baseline clinical data will be collected from all patients including 
proper history- History of Diabetes , Hypertension , angina , Chest 
pain duration and character, associated symptoms and other 
necessary history.  
3. The collected data of each patient will be collected in a specific 
proforma (ANNEXURE 1) which includes patient’s name , age, 
sex, demographic details , presenting complaints, risk factors and 
all the clinical data.  
4. The ECG and if necessary a 2D Echocardiogram will be performed 
for all patients to confirm STEMI. 
5. Blood sample will be collected at around 12 hours post admission 
in all STEMI patients and Troponin T Quantitative levels will be 
determined by ECLIA (ElectroChemiLuminescent Assay ) method 
and will be entered in the proforma . Fasting Lipid Profile will also 
be sent and the results entered in a proforma.  
6. Reference normal Troponin T is <0.01 ng/mL 
7. Repeat 2D Echocardiogram will be done for all patients , 48 hours 
post admission to determine EF and the value will then be recorded 
in the proforma.  
8. All the relevant data and values are then entered In a masterchart in 
Microsoft excel Format and then analyzed satistically. 
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STATISTICAL ANALYSIS 
 
The data was collected in the master chart obtained in the Microsoft excel 
format.  
 
The collected data was analysed with SPSS 16.0 version.To describe 
about the data descriptive statistics frequency analysis, percentage 
analysis were used for categorical variables and the mean & S.D 
were used for continuous variables. To find the significant difference 
between the bivariate samples in Independent groups the Mann-
Whitney U test was used. To assess the relationship between the 
variables Spearman's rank Correlation was used. In both the above 
statistical tools the probability value .05 is considered as significant 
level.  
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RESULTS 
    The total patients recruited in our study were 52.  The following charts 
depict frequency distributions.  
These are the frequency distributions of various variables used in our 
study .  
GENDER DISTRIBUTION : 
      In a total of 52 patients enrolled in our study 17 were females and 35 
were males and it clearly shows the predominance of males in STEMI. 
 
Frequency Percent 
 Female 17 32.7 
Male 35 67.3 
Total 52 100.0 
 
 
 
Female 
33% 
Male 
67% 
Gender Distribution 
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2. DISTRIBUTION OF DIABTES (D) , HYPERTENSION(H) AND 
ANGINA(A) PATIENTS ( ALONE AND IN COMBINATION : 
 
      In our study the frequency of diabetes alone was higher together with 
patients having neither diabetes  , hypertension or angina . 
 
  Frequency Percent 
 D 12 23.1 
D/A 3 5.8 
D/H 10 19.2 
D/H/A 2 3.8 
H 10 19.2 
H/A 3 5.8 
No 12 23.1 
Total 52 100.0 
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Key : D- Diabetes , H- Hypertension, A- Angina. 
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3. PATIENTS WITH SYSTOLIC BP < 100 mm of Hg : 
                  15 patients ( 28.8%) had a systolic BP of < 100 mm Hg .  
  Frequency Percent 
 No 37 71.2 
Yes 15 28.8 
Total 52 100.0 
 
 
 
 
 
No 
71% 
Yes 
29% 
SBP<100 
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4. PATIENTS WITH HEART RATE < 100 bpm : 
               20 patients ( 38.5%) of patients had a Heart rate of > 100 beats 
per minute.  
  Frequency Percent 
 No 32 61.5 
Yes 20 38.5 
Total 52 100.0 
 
 
 
 
 
No 
62% 
Yes 
38% 
HR<100 
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5. PATIENTS WITH WEIGHT <67kg : 
12 patients ( 23.1%) had weight < 67 kg. 
 
  Frequency Percent 
 No 40 76.9 
Yes 12 23.1 
Total 52 100.0 
 
 
  
 
 
No 
77% 
Yes 
23% 
Weight < 67 kg 
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6. KILLIP CLASS 2,3.4 : 
25 patients ( 48.1%) had a killip score of 2,3 or 4 . 
  Frequency Percent 
 No 27 51.9 
Yes 25 48.1 
Total 52 100.0 
    
 
7. PATIENTS WHO SMOKE : 
29 patients out of 52 ( 55.8%) were smokers . 
  Frequency Percent 
 No 23 44.2 
Yes 29 55.8 
Total 52 100.0 
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8. PATIENTS WHO ARE DYSLIPIDEMIC : 
 
             13 patients (25%) in our study were dyslipidemic.  
  Frequency Percent 
 No 39 75.0 
Yes 13 25.0 
Total 52 100.0 
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9. STEMI TYPE : 
               Out of 52 patients 22 patients were found out to be Inferior Wall 
MI or combinations of IWMI and 15 were found to have Anterior wall 
MI and only 1 patient had an isolated Posterior Wall MI. 
 
  Frequency Percent 
 ALMI 6 11.5 
ASMI 8 15.4 
AWMI 15 28.8 
IWMI 6 11.5 
IWMI+PWMI 7 13.5 
IWMI+PWMI+RVMI 1 1.9 
IWMI+RVMI 7 13.5 
IWMI+RVMI+PWMI 1 1.9 
PWMI 1 1.9 
Total 52 100.0 
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KEY : PWMI- Posterior wall Myocardial Infarction  
           RVMI- Right Ventricular Myocardial Infarction  
           IWMI- Inferior Wall Myocardial Infarction 
           AWMI- Anterior Wall Myocardial Infarction 
           ALMI- AnteroLateral Myocardial Infarction 
           ASMI- AnteroSeptal Myocardial Infarction 
          STEMI- ST Elevation Myocardial Infarction 
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10. PATIENTS WITH NEW LBBB : 
 
Only 3 patients in our study had a new onset LBBB ( Left Bundle 
Branch Block ) in ECG. 
  Frequency Percent 
 No 49 94.2 
Yes 3 5.8 
Total 52 100.0 
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Yes 
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New LBBB 
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11. PATIENTS WITH TIME TO TREAT > 4 HOURS  
 
    In our study all the enrolled patients were treated with thrombolysis 
before 4 hours .  
 
Frequency Percent 
 No 52 100.0 
 
12. PATIENTS WITH EJECTION FRACTION < 40% : 
 
23 patients ( 44.2%) in our study had an EF of < 40%.  
  Frequency Percent 
 No 29 55.8 
Yes 23 44.2 
Total 52 100.0 
 
 
No 
56% 
Yes 
44% 
EF < 40% at 48 hrs 
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13.  AGE RANGE : 
 
The age range in our study id depicted in the following table and bar 
diagram.  
 
  Frequency Percent 
 < 45 
yrs 
10 19.2 
45 - 60 
yrs 
25 48.1 
> 60 
yrs 
17 32.7 
Total 52 100.0 
 
It can be noted that the maximum events in our study occurred in the 45-
60 age group .  
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Age range – Note thst the maximum number of events occurred in the 45-
60 age roup in our study ( NB:This may be biased as the we take in to 
account only the number of patients reaching the hospital . It does not 
take into account the patients who do not report after an MI or patiemts 
who die before reaching the hospital ) 
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14. THROMBOLYSIS IN MYOCARDIAL INFARCTION SCORE :  
 
  Frequency Percent 
 0 6 11.5 
1 6 11.5 
2 7 13.5 
3 3 5.8 
4 9 17.3 
5 2 3.8 
6 7 13.5 
7 2 3.8 
8 2 3.8 
9 6 11.5 
10 2 3.8 
Total 52 100.0 
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STATISTICAL ANALYSIS : 
 
     The total patients enrolled in our study were 52 . The maximum age is 
76 and the minimum is 36. In the male patients maximum age recorded 
was 71 and the minimum age was 36 where as in the females it is 76 and 
42 respectively. 
 
1. CORRELATION OF TIMI SCORE AT THE TIME OF 
ADMISSION AND SINGLE QUANTITAIVE TROPONIN T AT 
12 HOURS  :  
         TIMI score for acute STEMI which was calculated at the time 
of admission was correlated with Single Quantitative Troponin T at 
12 hours using non parametric correlations using correlation 
coefficient . It was then statistically tested using spearman’s rho ( sig 
two tailed ) and the correlation is taken to be significant at a p value 
of 0.05 .  
           In our study the correlation between TIMI score for acute 
STEMI at the time of admission and with Single Quantitative 
Troponin T at 12 hours was found to be highly significant at p=0.005. 
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 From the graph , it was evident at that the correlation between TIMI 
score at the time of admission and TIMI score at 48 hours is 
statistically significant .  
 
 
 
 
 
 
 84 
2. ASSOCIATION BETWEEN TIMI SCORE AT THE TIME OF 
ADMISSION AND EJECTION FRACTION < /> 40 % at 48 
hours :  
              The association between TIMI score at the time of admission 
and EF < 40 % was tested using Mann – Whitney U test.  Those with 
EF> 40% at 48 hours had a mean TIMI score of 2.17 during 
admission and those with EF <40% at 48 hours had a mean TIMI 
score of 6.87 during admission . 23 patients had a EF of < 40% at 48 
hours and 29 patients had a EF>40% at 48 hours. The association was 
found to be statistically significant at p=0.005.  
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3. ASSOCIATION BETWEEN TROPONIN T AT 12 HOURS AND 
EJECTION FRACTION < /> 40% AT 48 HOURS :  
                  The association between Troponin T at 12 hours and Ejection 
fraction < 40 or >40% was tested again using Mann Whitney U test. 
Those with Ejection fraction<40% at 48 hours had a mean Troponin T of  
1.74 ng/mL at 12 hours and those with EF > 40% at 48 hours had a mean 
Troponin T level of 1.74 at 12 hours. The association was found o be 
statistically significant at p=0.005. 
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The association between all three variables is depicted in the chart below. 
 
EF <40% 
Mean TIMI score at 
admission 
No 2.17 
 Yes 6.87 
 
   
 
Mean Trop T at 12 hours 
No 1.25 
 Yes 1.74 
 
 
     All the aforementioned statistics confirms that the correlation between  
1. TIMI score at the time of admission and Troponin T at 12 hours 
2. The association between Troponin T at 12 hours and EF <40% at 
48 hours  
3. The association between TIMI score at the time of admission and 
EF<40% at 48 hours. 
       These are also found to be highly significant statistically at 
p=0.005.  
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   Further Statistical data were obtained to confirm the results and exclude 
the possible confounders like smoking and duslipidemia . 
 
1. CORRELATION BETWEEN TIMI SCORE AT THE TIME 
OF ADMISSION AND THE TYPE OF MI :  
          The TIMI score at the time of admission was correlated 
with the type of MI . First MI was classified into two types- 
those involving anterior wall (AWMI,ASMI.ALMI) and those 
involving Inferior wall (IWMI,IWMI+RVMI, 
IWMI+RVMI+PWMI,IWMI+PWMI, isolated PWMI). This 
analysis was actually done to find out the correlation as well as 
VALIDATE THE TIMI SCORE with its variables as one of the 
variable is the presence of AWMI. The mean TIMI score for 
5.45 for AWMI’s and 2.74 for IWMI’s at the time of admission. 
The results were tested using Mann Whitney U test and was 
found to be statistically significant at p=0.001.   
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And also since points awarded for AWMI was only 1 in the TIMI score , 
the difference in our study was actually around 2.71. This maybe due to 
the fact that AWMI is usually severe with involvement of other variables 
like SBP, HR amd Killip class used in the TIMI score. That might need a 
separate Study and further evaluation. 
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6,00
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TIMI score at admission 
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2. TIMI score and its association with Smoking : 
       This was done actually to find out smoking as a potential 
confounder in altering one or more components of the TIMI score . 
In our study 29 were smokers and 23 were non smokers out of a 
total of 52 patients. The mean TIMI score in Smokers were found 
to be 4.07 and mean TIMI score in non smokers were found to be 
4.48 and the results are tested with Mann Whitney U test and are 
found to be Statistically NOT significant at p=0.774.  
 
 
 
 
 
 
4,48 
4,07 
3,80
3,90
4,00
4,10
4,20
4,30
4,40
4,50
4,60
No Yes
TIMI score at admission with Smoking habit 
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3. Troponin T and its association with Smoking : 
             This was done actually to find out smoking as a potential 
confounder in altering the Troponin T values considerably. It was found 
that the smokers had a mean Troponin T value of 1.45 ng/mL at 12 hours 
and non smokers had a mean troponin T value of 1.48 ng/mLat 12 hours 
and the results were tested using mann Whitney U test and it is found to 
be statistically NOT significant at p= 0.956.
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4. Association of dyslipidemia with TIMI score at admission and 
Troponin T at 12 hours : 
                    This was also done to find out whether dyslipidemia affects 
TIMI score and Troponin T . It is found out that patients with 
dyslipidemia had a mean TIMI score of 5.85 at the time of admission at 
p=0.048 and a mean Troponin T value of 1.59 ng/mL at 12 hours at 
p=0.131 and both were statistically not significant as p>0.01 was 
considered to be statistically insignificant. Patients without dyslipidemia 
had a mean TIMI score of 3.72 at the time of admission at p=0.048 and a 
mean Troponin T value of 1.42ng/mL at 48 hours at p=0.131. Both were 
tested using Mann Whitney U test . The results were depicted below.  
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5. Association of EF<40% with Smoking and dyslipidemia :  
The association of Smoking and dyslipidemia with EF<40% were tested 
individually using Chi square tests and the association was found to be 
statistically not significant at p=0.922 ( for smoking and EF>40%) and 
p=0.036 ( for dydlipidemia and F<40%). 
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DISCUSSION 
 
       Acute Coronary Syndrome is a spectrum of disorders which include 
ST Elevation Myocardial Infarction (STEMI), Non ST Elevation 
Myocardial Infarction(NSTEMI) and Unstable Angina (UA). STEMI is 
usually associated with significant short term as well as long term 
mortality . STEMI is diagnosed by characteristic ECG changes along 
with clinical features and elevation of cardiac biomarkers.1 
        There are a lot of prognostic markers available for ST Elevstion 
Myocardial Infarction . But the Thrombolysis In Myocardial Infarction 
(TIMI) score is clinical and was widely known to predict prognosis in the 
form of mortality at 30 days. TIMI score8 uses simple clinical data , and 
its calculation is simple and entirely bedside and it it can be assessed 
through simple clinical examination and history 4 
         The Troponin T which is used as a biomarker for diagnosing 
STEMI , can also be used as a prognostic marker based on the value of 
Troponin T at various points post MI13. Usually the levels of Troponin T 
at 12, 24 ,48 or 72 hours can be taken to predict the prognosis. Troponin 
T is releases from the cardiac myocytes upon death/lysis usually during 
infarction) . So the absolute Troponin T levels can predict the size of the 
infarct in MI and especially STEMI. The infarct size is a well known 
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predictor of severity and it is directly proportional to the mortality and 
morbidity and hence widely used as a prognostic marker .  
         The Ejection fraction32 has long been recognized as a prognostic 
indicator. Roughly an Ejection fraction of <40% has been shown by a 
number of studies as an indicator of poor prognosis and increased long 
term and short term mortality and morbidity. Even though its usefulness 
has been questioned in recent times , it is still regarded as an important 
prognostic variable. 
          There are numerous other prognostic variables but in our study we 
use only TIMI score30 , Troponin T and Ejection fraction <40%. Since 
TIMI score is entirely clinical we evaluated the associations between 
these three variables so that we can predict the other two using TIMI 
score itself which is calculated at the time of admission. There were no 
previous studies made in regard to this association.  
      Total of 52 patients were enrolled in our study over a period of 6 
months and 17 were females and 35 were males . We obtained a standard 
questionairre mentioning all the data and variables used in the TIMI score 
as well as ejection fraction <40% obtained at 48 hours and Quantitative 
Troponin T obtained at 12 hours. We considered smoking and 
dyslipidemia as potential confounders and hence added to the list . The 
collected data was analysed with SPSS 16.0 version 
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              In our study the frequency of diabetes alone was higher together 
with patients having neither diabetes  , hypertension or angina , 15 
patients ( 28.8%) had a systolic BP of < 100 mm Hg, 20 patients ( 38.5%) 
of patients had a Heart rate of > 100 beats per minute, 12 patients ( 
23.1%) had weight < 67 kg,              25 patients ( 48.1%) had a killip 
score of 2,3 or 4, 29 patients out of 52 ( 55.8%) were smokers , 13 
patients (25%) in our study were dyslipidemic , 22 patients were found 
out to be Inferior Wall MI or combinations of IWMI and 15 were found 
to have Anterior wall MI and only 1 patient had an isolated Posterior 
Wall MI, Only 3 patients in our study had a new onset LBBB ( Left 
Bundle Branch Block ) in ECG.    In our study all the enrolled patients 
were treated with thrombolysis before 4 hours .  
        23 patients ( 44.2%) in our study had an EF of < 40%. The 
maximum age is 76 and the minimum is 36. In the male patients 
maximum age recorded was 71 and the minimum age was 36 where as in 
the females it is 76 and 42 respectively. 
         The correlation and association was done between all possible 
variables . Correlation was done between TIMI score at the time of 
admission and Single Quantitative Troponin T at 12 hours. In our study 
the correlation between TIMI score for acute STEMI at the time of 
admission and with Single Quantitative Troponin T at 12 hours was 
found to be highly significant at p=0.005. Association between TIMI 
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score and EF<40% at 48 hours was tested and the association was found 
to be statistically significant at p=0.005. Those with EF> 40% at 48 hours 
had a mean TIMI score of 2.17 during admission and those with EF 
<40% at 48 hours had a mean TIMI score of 6.87 during admission . 23 
patients had a EF of < 40% at 48 hours and 29 patients had a EF>40% at 
48 hours. The association between Troponin T at 12 hours and EF<40% 
at 48 hours was then tested and the association was found o be 
statistically significant at p=0.005. “Those with Ejection fraction<40% at 
48 hours had a mean Troponin T of  1.74 ng/mL at 12 hours and those 
with EF > 40% at 48 hours had a mean Troponin T level of 1.74 at 12 
hours.” 
55 
        The TIMI score at the time of admission was then correlated with 
the type of MI . The mean TIMI score is 5.45 for AWMI’s and 2.74 for 
IWMI’s at the time of admission. The results were found to be 
statistically significant at p=0.001.   
        The association between potential confounders – smoking and 
dyslipidemia was then done. The mean TIMI score in Smokers were 
found to be 4.07 and mean TIMI score in non smokers were found to be 
4.48 and the results were found to be Statistically NOT significant at 
p=0.774. The association between Smoking and Troponin T was then 
done. It was found that the smokers had a mean Troponin T value of 1.45 
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ng/mL at 12 hours and non smokers had a mean troponin T value of 1.48 
ng/mLat 12 hours and the results were tested using mann Whitney U test 
and it is found to be statistically NOT significant at p= 0.956. 
        The association between TIMI score and dyslipidemia was then 
done. It is found out that patients with dyslipidemia had a mean TIMI 
score of 5.85 at the time of admission at p=0.048 and a mean Troponin T 
value of 1.59 ng/mL at 12 hours at p=0.131 and both were statistically not 
significant as p>0.01 was considered to be statistically insignificant. 
Patients without dyslipidemia had a mean TIMI score of 3.72 at the time 
of admission at p=0.048 and a mean Troponin T value of 1.42ng/mL at 
48 hours at p=0.131 
           Lastly , the association of EF <40% with smoking and 
dyslipidemia was sought for. The association of Smoking and 
dyslipidemia with EF<40% were tested individually using Chi square 
tests and the association was found to be statistically not significant at 
p=0.922 ( for smoking and EF>40%) and at p=0.036 ( for dydlipidemia 
and F<40%). 
           Since our study is totally new ( TIMI score have not been 
compared with Troponin T or Ejection fraction ) and have not been 
performed in the past , we did not find any control studies to compare our 
study with their experiences. We consider this as a potential disadvantage 
of our study and so this study might need further studies to confirm 
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positive and negative associations found in our study. We believe that 
will happen in the near future.  
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CONCLUSION 
 
1. TIMI score calculated at the time of admission has significant 
correlation with Single Quantitative Troponin T at 12 hours post 
admission. (p=0.005) 
2. TIMI score calculated at the time of admission also has significant 
association with Ejection Fraction < 40% at 48 hours post 
admission . (p=0.005) 
3. Single Quantitative Troponin T obtained 12 hours post admission 
has significant association with Ejection Fraction < 40% at 48 
hours post admission (p=0.005) 
4. There is no statistically significant association between smoking 
and TIMI score at admission , Troponin T at 12 hours or Ejection 
Fraction < 40% at 48 hours.  
5. There is no statistically significant association between 
dyslipidemia and TIMI score , Troponin T at 12 hours or Ejection 
Fraction<40% at 48 hours.
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ANNEXURE -2 
MASTER CHART
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Sl 
no 
Name Age S
e
x 
Diabetes(D), 
Hypertensio
n (H), 
Angina(A) 
SBP<1
00 
Mm 
hg 
HR>
100 
bpm 
Killip 
Class 
2,3,4 
Weight 
<67 kg 
STEMI 
type 
New 
LBBB 
Time to 
treat > 
4 hours 
Smoking Dyslipidemia TIMI score 
at 
admission 
Trop 
T at 
12 
hours 
EF<4
0%a
t 48 
hrs 
1. Srinivasan 43 M No Yes  Yes Yes No AWMI No No No Yes 8 1.76 Yes 
2. Venugopal 56 M D/H No No No No IWMI No No Yes Yes 2 1.21 No 
3.  Sankaran 61 M D/A No No No No IWMI+
RVMI 
No No Yes No 2 1.31 No 
4.  AdhiRaj 52  M No No Yes  Yes  No ASMI Yes No Yes Yes 6 1.72 Yes 
5. Mangalam 59 F D/A Yes Yes Yes Yes ALMI No No No No 9 2.21 Yes 
6. Siva Kumar 36 M No Yes Yes Yes Yes AWMI No No Yes Yes 9 1.97 Yes 
7. Meenakshi 52 F D/H No No No No IWMI No No No No 2 1.31 No 
8. Sundaram 40  M D No No No No IWMI+P
WMI+R
VMI 
No No Yes No 1 0.98 No 
9. Adikesavan 69 M D/H/A Yes No No Yes IWMI+P
WMI 
No No Yes No 5 1.79 No 
10.  Mary 62 F D Yes Yes Yes Yes AWMI No No No No 10 2.11 Yes 
11.  Alamelu 76 F D/H/A No Yes Yes Yes ASMI No No No  No 10 2.24 Yes 
12. Sekar 51 M H/A No No Yes No ASMI No No Yes No 4 1.59 Yes 
13.  Rizwan 41 M No No No No No IWMI+
RVMI 
No No No No 0 0.96 No 
14.  Gowri 49 F H No No Yes No AWMI No No No  No 4 1.52 No 
15. Raja 54 M D/H Yes No No Yes IWMI+P
WMI 
No No Yes Yes 5 1.44 No 
16. Jeevaraj 44 M H No No No No ASMI No No Yes No 2 1.48 No 
17. Subraja 68 F H Yes Yes Yes No ALMI No No No No 7 1.77 Yes 
Sl 
no 
Name Age S
e
x 
Diabetes(D), 
Hypertensio
n (H), 
Angina(A) 
SBP<1
00 
Mm 
hg 
HR>
100 
bpm 
Killip 
Class 
2,3,4 
Weight 
<67 kg 
STEMI 
type 
New 
LBBB 
Time to 
treat > 
4 hours 
Smoking Dyslipidemia TIMI score 
at 
admission 
Trop 
T at 
12 
hours 
EF<4
0% 
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18. Anthony 53 M H No Yes Yes No AWMI No No Yes No 6 1.67 Yes 
19. Chinna 
Ponnu 
68 F D/H Yes No Yes Yes IWMI+
RVMI 
No No No Yes 9 1.61 Yes 
20. Azharrudin 58 M No No No Yes No ASMI No No Yes No 3 1.32 No 
21.  Singaram 64 M D/H No No No No AWMI No No Yes No 1 1.49 No 
22.  Pichai 59 M H Yes Yes No NO IWMI No No No No 6 1.66 Yes 
23.  Akilandam 55 F D/H No No No No IWMI+
RVMI 
No No No No 0 1.16 No 
24.   Saraswathy 59 F No No No No No IWMI+P
WMI 
No No No Yes 0 0.88 Yes 
25.  Rangan 68 M H Yes No Yes Yes IWMI+
RVMI 
No No Yes No 8 1.71 Yes 
26.  Azhagar 71 M D/H No Yes Yes Yes AWMI No No Yes Yes 9 1.86 Yes 
27.  Tamilselvi 66 F D/A No No No No AWMI No No No No 4 1.34 No 
28.  Saminathan  71  M D No Yes Yes No ASMI No No Yes No 6 1.73 Yes 
29. Aruna  55 F H/A No No No No AWMI No No No No 0 1.02 No 
30. Adhithyan 61 M D No Yes No No ALMI No No Yes No 3 1.34 No 
31.  Ilayaraja 58 M D/H Yes No No No IWMI+P
WMI 
No No Yes No 4 1.33 Yes 
32.  Sadhiq 
Basha  
55 M No No No No Yes IWMI No No Yes No 1 0.99 No 
33. Ramesh 46 M D Yes Yes Yes No AWMI Yes No Yes Yes 9 1.98 Yes 
Sl 
no 
Name Age S
e
x 
Diabetes(D), 
Hypertensio
n (H), 
Angina(A) 
SBP<1
00 
Mm 
hg 
HR>
100 
bpm 
Killip 
Class 
2,3,4 
Weight 
<67 kg 
STEMI 
type 
New 
LBBB 
Time to 
treat > 
4 hours 
Smoking Dyslipidemia TIMI score 
at 
admission 
Trop 
T at 
12 
hours 
EF<4
0% 
34. Saravanan 38 M No Yes Yes No No ALMI No No Yes No 6 1.77 Yes 
35.  Arivukozhu
ndhu 
66 F D No No No No ASMI Yes No No No 4 1.29 No 
36.  Adalarasan 48 M H No No Yes No AWMI No No Yes No 4 1.33 Yes 
37.  Yasir Khan 56 M D Yes No Yes No IWMI+P No No Yes No 6 1.48 Yes 
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WMI 
38. Arikrishnan 54 M D No No No No IWMI+
RVMI+P
WMI 
No No No No 1 1.17 No 
39. Munusamy 41 M No  No No No No ASMI No No Yes No 1 0.89 No 
40. Arokia Mary 56 F H Yes Yes Yes No AWMI No No No Yes 9 2.11 Yes 
41. Anthony 42 M No No Yes Yes No IWMI+
RVMI 
No No Yes No 4 1.29 No 
42. Anandhan 46 M H No No No No IWMI+P
WMI 
No No Yes No 0 1.01 No 
43.  Rajesh 39 M No No Yes No No ALMI No No Yes No 3 1.49 No 
44. Kalaiselvi 42 F D No No Yes No IWMI No No No No 2 1.11 No 
45.  Nandha 
Kumar 
67 M D/H No Yes Yes Yes AWMI No No No No 7 1.77 Yes 
46.  Maheswari 61 F D/H No No No Yes PWMI No No No No 1 1.03 No 
47. Siva 
Sridharan 
47 M H No Yes No No AWMI No No No No 4 1.41 No 
Sl 
no 
Name Age S
e
x 
Diabetes(D), 
Hypertensio
n (H), 
Angina(A) 
SBP<1
00 
Mm 
hg 
HR>
100 
bpm 
Killip 
Class 
2,3,4 
Weight 
<67 kg 
STEMI 
type 
New 
LBBB 
Time to 
treat > 
4 hours 
Smoking Dyslipidemia TIMI score 
at 
admission 
Trop 
T at 
12 
hours 
EF<4
0% 
48. Manickam 50 M D No Yes Yes No ALMI No No Yes Yes 6 1.71 Yes 
49. Sasikala  61 F H/A No No Yes No AWMI No No No Yes 4 1.42 No 
50.  Mala 69 F D No No No No IWMI+
RVMI 
No No No No 2 1.12 No 
51. Murugan 53 M No No No Yes No IWMI+P
WMI 
No No Yes No 2 1.24 No 
52.  Raman  51 M D No No No No IWMI No No Yes Yes 0 1.00 No 
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KEYS TO MASTER CHART  
 
M- Male 
F- Female 
D- Diabetes 
H- Hypertension 
A- Angina 
SBP- Systolic Blood Pressure 
 
HR- Heart Rate 
STEMI- ST Elevation Myocardial Infarction 
TIMI – Thrombolysis In Myocardial Infarction 
LBBB- Left Bundle Branch Block 
Trop T- Troponin T 
EF- Ejection fraction 
AWMI- Anterior Wall Myocardial Infarction 
ASMI- AnteroSeptal Myocardial Infarction 
ALMI- AnteroLateral Myocardial Infarction 
IWMI- Inferior Wall Myocardial Infarction 
RVMI- Right Ventrivular Myocardial Infarction 
PWMI- Posterior Wall Myocardial Infarction 
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ANNEXURE – 3 
ETHICAL COMMITTEE CLEARANCE CERTIFICATE  
 
